Evidence has been reported that CB2R agonists have an inhibitory effect on tumor cell growth and lead to tumor cell death in vivo and in vitro: the mechanisms responsible for these actions are not fully elucidated but have been related to the inhibition of vascular growth factor (VEGF) produced by tumor cells, reduction in the proteolytic matrix metalloproteinases MMP1, MMP2, and MMP9, and inhibition of angiopoietin 2 [120,121]. Here, MMP9 is linked to neoplasm.